Editas Medicine, Inc. (EDIT)
3.07
-0.01
(-0.32%)
USD |
NASDAQ |
Sep 03, 16:00
3.115
+0.04
(+1.47%)
After-Hours: 20:00
Editas Medicine Research and Development Expense (TTM) : 82.53M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 82.53M |
| March 31, 2026 | 77.12M |
| December 31, 2025 | 84.68M |
| September 30, 2025 | 105.31M |
| June 30, 2025 | 132.29M |
| March 31, 2025 | 170.74M |
| December 31, 2024 | 193.44M |
| September 30, 2024 | 214.30M |
| June 30, 2024 | 207.26M |
| March 31, 2024 | 182.70M |
| December 31, 2023 | 171.59M |
| September 30, 2023 | 153.92M |
| June 30, 2023 | 154.64M |
| March 31, 2023 | 168.46M |
| December 31, 2022 | 168.62M |
| September 30, 2022 | 154.24M |
| June 30, 2022 | 142.60M |
| March 31, 2022 | 133.10M |
| December 31, 2021 | 137.45M |
| September 30, 2021 | 161.74M |
| June 30, 2021 | 166.47M |
| March 31, 2021 | 161.04M |
| Date | Value |
|---|---|
| December 31, 2020 | 154.04M |
| September 30, 2020 | 127.72M |
| June 30, 2020 | 116.89M |
| March 31, 2020 | 113.32M |
| December 31, 2019 | 95.39M |
| September 30, 2019 | 80.58M |
| June 30, 2019 | 76.04M |
| March 31, 2019 | 85.20M |
| December 31, 2018 | 89.90M |
| September 30, 2018 | 96.42M |
| June 30, 2018 | 98.69M |
| March 31, 2018 | 83.29M |
| December 31, 2017 | 81.13M |
| September 30, 2017 | 81.77M |
| June 30, 2017 | 72.61M |
| March 31, 2017 | 65.72M |
| December 31, 2016 | 56.21M |
| September 30, 2016 | 35.69M |
| June 30, 2016 | 28.99M |
| March 31, 2016 | 25.84M |
| December 31, 2015 | 18.85M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Recursion Pharmaceuticals, Inc. | 344.11M |
| Geron Corp. | 73.89M |
| Halozyme Therapeutics, Inc. | 102.37M |
| Novavax, Inc. | 335.42M |
| AVITA Medical, Inc. | 20.15M |